N,N-diethyl-4-(((pyridin-3-ylmethyl)amino)methyl)aniline | 510723-51-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-diethyl-4-(((pyridin-3-ylmethyl)amino)methyl)aniline
• 英文别名: Diethyl-(4-{[(pyridin-3-ylmethyl)-amino]-methyl}-phenyl)-amine；N,N-diethyl-4-[(pyridin-3-ylmethylamino)methyl]aniline
• CAS: 510723-51-0
• 化学式: C₁₇H₂₃N₃
• 分子量: 269.39
• InChiKey: ULNFGTGKYQAVCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  2-喹喔啉甲酰氯 、 N,N-diethyl-4-(((pyridin-3-ylmethyl)amino)methyl)aniline 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以72%的产率得到N-(4-(diethylamino)benzyl)-N-(pyridin-3-ylmethyl)quinoxaline-2-carboxamide
  参考文献：
  名称：

  [EN] NOVEL CANNABINOID RECEPTOR CB2 LIGAND 4-(AMINOMETHYL)-N,N-DIALKYLANILINES
  [FR] NOUVEAU LIGAND DE TYPE 4-(AMINOMÉTHYL)-N,N-DIALKYLANILINES POUR RÉCEPTEUR DE CANNABINOÏDES CB2

  摘要：

  本文披露了由式(I)表示的新型大麻素受体-2（CB2）激动剂和反向激动剂，以及通过将式(I)的化合物与CB-2受体接触来调节CB2活性的方法。此外，还披露了通过调节大麻素受体-2（CB2）活性来治疗哺乳动物中的多发性骨髓瘤或骨质疏松症的方法。

  公开号：

  WO2016205707A1
• 作为产物：
  描述：

  N,N-二乙基-4-氨基苯甲醛 在 甲醇 、 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 N,N-diethyl-4-(((pyridin-3-ylmethyl)amino)methyl)aniline
  参考文献：
  名称：

  [EN] NOVEL CANNABINOID RECEPTOR CB2 LIGAND 4-(AMINOMETHYL)-N,N-DIALKYLANILINES
  [FR] NOUVEAU LIGAND DE TYPE 4-(AMINOMÉTHYL)-N,N-DIALKYLANILINES POUR RÉCEPTEUR DE CANNABINOÏDES CB2

  摘要：

  本文披露了由式(I)表示的新型大麻素受体-2（CB2）激动剂和反向激动剂，以及通过将式(I)的化合物与CB-2受体接触来调节CB2活性的方法。此外，还披露了通过调节大麻素受体-2（CB2）活性来治疗哺乳动物中的多发性骨髓瘤或骨质疏松症的方法。

  公开号：

  WO2016205707A1

文献信息

• Screening of a series of 3,5-disubstituted 1,2,4-thiadiazoles for selectivity of cytotoxic action to cancer cells
  作者：A. N. Proshin、T. P. Trofimova、O. N. Zefirova、I. V. Zhirkina、D. A. Skvortsov、S. O. Bachurin

  DOI：10.1007/s11172-021-3116-4

  日期：2021.3

  New 3,5-disubstituted-1,2,4-thiadiazoles were synthesized and together with a series of their analogs obtained earlier were tested for cytotoxic activity to breast adenocarcinoma MCF-7 and lung carcinoma A 549 cells. The selectivity of cytotoxic action was determined in comparison to etiologically noncancerous breast epithelial cells MCF-10A and lung fibroblasts VA13. From five- to six-fold selectivity of cytotoxic action was revealed for 3,4-dichlorophenyl-3-[2-(2-morpholin-4-ylethylamino)propyl]-[1,2,4]thiadiazol-5-yl}amine and (2-5-[(4-diethylami-nobenzyl)pyridin-3-ylmethylamino]-[1,2,4]thiadiazol-3-yl}-1-methylvinyl)-(2,2,6,6-tetra-methylpiperidin-4-yl)amine in the pairs A 549/VA13 and MCF-7/MCF-10A, respectively. Some structure—property relationships for the compounds under study were discussed.

  合成了新的 3,5-二取代-1,2,4-噻二唑，并与之前获得的一系列类似物一起测试了对乳腺癌 MCF-7 和肺癌 A 549 细胞的细胞毒活性。与病因学上的非癌性乳腺上皮细胞 MCF-10A 和肺成纤维细胞 VA13 相比，确定了细胞毒作用的选择性。 3,4-二氯苯基-3-[2-(2-吗啉-4-基乙基氨基)丙基]-[1,2,4]噻二唑-5-基的细胞毒性作用选择性提高了五到六倍}胺和(2-5-[(4-二乙基氨基苄基)吡啶-3-基甲基氨基]-[1,2,4]噻二唑-3-基}-1-甲基乙烯基)-(2,2,6, 6-四甲基哌啶-4-基)胺分别为 A 549/VA13 和 MCF-7/MCF-10A 对。讨论了所研究化合物的一些结构-性质关系。
• Cannabinoid receptor CB2 ligand 4-(aminomethyl)-N,N-dialkylanilines
  申请人：UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US10696624B2

  公开（公告）日：2020-06-30

  Disclosed herein are novel cannabionid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).

  本文公开了由式（I）代表的新型大麻素受体-2（CB2）激动剂和逆激动剂，以及通过使 CB-2 受体与式（I）化合物接触来调节 CB2 活性的方法。此外，还公开了通过调节大麻素受体-2（CB2）的活性来治疗有需要的哺乳动物的多发性骨髓瘤或骨质疏松症的方法。
• Cannabinoid receptor CB2 ligand 4-(aminomethyl)-N, N-dialkylanilines
  申请人：UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US11059778B2

  公开（公告）日：2021-07-13

  Disclosed herein are novel cannabionid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).

  本文公开了由式（I）代表的新型大麻素受体-2（CB2）激动剂和逆激动剂，以及通过使 CB-2 受体与式（I）化合物接触来调节 CB2 活性的方法。此外，还公开了通过调节大麻素受体-2（CB2）的活性来治疗有需要的哺乳动物的多发性骨髓瘤或骨质疏松症的方法。
• NOVEL CANNABINOID RECEPTOR CB2 LIGAND 4-(AMINOMETHYL)-N,N-DIALKYLANILINES
  申请人：UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US20180141902A1

  公开（公告）日：2018-05-24

  Disclosed herein are novel cannabinoid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).
• NOVEL CANNABINOID RECEPTOR CB2 LIGAND 4-(AMINOMETHYL)-N, N-DIALKYLANILINES
  申请人：UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US20200270205A1

  公开（公告）日：2020-08-27

  Disclosed herein are novel cannabionid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).